Heide L. Ford - Publications

Affiliations: 
Molecular Biology University of Colorado Anschutz Medical Campus, Denver, Aurora, CO 
Area:
Oncology, Molecular Biology

63/101 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Anantharajan J, Zhou H, Zhang L, Hotz T, Vincent MY, Blevins MA, Jansson AE, Liang Kuan JW, Ng EY, Yeo K, Baburajendran N, Lin G, Hung AW, Joy J, Patnaik S, ... ... Ford HL, et al. Structural and functional analyses of an allosteric Eya2 phosphatase inhibitor that has on target effects in human lung cancer cells. Molecular Cancer Therapeutics. PMID 31285279 DOI: 10.1158/1535-7163.MCT-18-1239  0.52
2019 Oliphant MUJ, Vincent MY, Galbraith MD, Pandey A, Zaberezhnyy V, Rudra P, Johnson KR, Costello JC, Ghosh D, DeGregori J, Espinosa JM, Ford HL. Six2 mediates late-stage metastasis via direct regulation of Sox2 and induction of a cancer stem cell program. Cancer Research. PMID 30606720 DOI: 10.1158/0008-5472.CAN-18-1791  0.44
2018 Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, Lewis MT, Ford HL. Publisher Correction: EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nature Communications. 9: 4720. PMID 30420638 DOI: 10.1038/s41467-018-07168-z  0.44
2018 Zhang L, Zhou H, Li X, Vartuli RL, Rowse M, Xing Y, Rudra P, Ghosh D, Zhao R, Ford HL. Author Correction: Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression. Nature Communications. 9: 3830. PMID 30224630 DOI: 10.1038/s41467-018-06265-3  0.52
2018 Vartuli RL, Zhou H, Zhang L, Powers RK, Klarquist J, Rudra P, Vincent MY, Ghosh D, Costello JC, Kedl RM, Slansky JE, Zhao R, Ford HL. Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. The Journal of Clinical Investigation. PMID 29757193 DOI: 10.1172/JCI96784  0.52
2018 Zhang L, Zhou H, Li X, Vartuli RL, Rowse M, Xing Y, Rudra P, Ghosh D, Zhao R, Ford HL. Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression. Nature Communications. 9: 1047. PMID 29535359 DOI: 10.1038/s41467-018-03327-4  0.52
2017 Zhou H, Zhang L, Vartuli RL, Ford HL, Zhao R. The Eya phosphatase: Its unique role in cancer. The International Journal of Biochemistry & Cell Biology. PMID 28887153 DOI: 10.1016/j.biocel.2017.09.001  0.52
2017 Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, Lewis MT, Ford HL. EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nature Communications. 8: 15773. PMID 28604738 DOI: 10.1038/ncomms15773  0.44
2017 Dimberg L, Towers CG, Behbakht K, Hotz T, Kim J, Fosmire SP, Porter CC, Tan AC, Thorburn A, Ford HL. A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance. Molecular Cancer Research : McR. PMID 28108622 DOI: 10.1158/1541-7786.MCR-16-0234  0.68
2016 Kendrick AA, Schafer J, Dzieciatkowska M, Nemkov T, Alessandro AD, Neelakantan D, Ford HL, Pearson CG, Weekes CD, Hansen KC, Eisenmesser EZ. CD147: a small molecule transporter ancillary protein at the crossroad of multiple hallmarks of cancer and metabolic reprogramming. Oncotarget. PMID 28039486 DOI: 10.18632/oncotarget.14272  0.44
2016 Zhou H, Neelakantan D, Ford HL. Clonal cooperativity in heterogenous cancers. Seminars in Cell & Developmental Biology. PMID 27582427 DOI: 10.1016/j.semcdb.2016.08.028  0.44
2016 Towers CG, Ford HL. A tale of two ends. Cell Cycle (Georgetown, Tex.). 0. PMID 27101085 DOI: 10.1080/15384101.2016.1171652  1
2015 Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MU, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, ... Ford HL, et al. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. Nature Communications. 6: 10077. PMID 26687066 DOI: 10.1038/ncomms10077  1
2015 Drasin DJ, Guarnieri AL, Neelakantan D, Kim J, Cabrera JH, Wang CA, Zaberezhnyy V, Gasparini P, Cascione L, Huebner K, Tan AC, Ford HL. TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. Cancer Research. 75: 1908-21. PMID 25716682 DOI: 10.1158/0008-5472.CAN-14-2394  1
2015 Blevins MA, Towers CG, Patrick AN, Zhao R, Ford HL. The SIX1-EYA transcriptional complex as a therapeutic target in cancer. Expert Opinion On Therapeutic Targets. 19: 213-25. PMID 25555392 DOI: 10.1517/14728222.2014.978860  1
2014 Neelakantan D, Drasin DJ, Ford HL. Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis. Cell Adhesion & Migration. 1-12. PMID 25482627 DOI: 10.4161/19336918.2014.972761  1
2014 Wang CA, Harrell JC, Iwanaga R, Jedlicka P, Ford HL. Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3. Breast Cancer Research : Bcr. 16: 462. PMID 25358638 DOI: 10.1186/s13058-014-0462-2  0.76
2014 Wang CA, Drasin D, Pham C, Jedlicka P, Zaberezhnyy V, Guney M, Li H, Nemenoff R, Costello JC, Tan AC, Ford HL. Homeoprotein Six2 promotes breast cancer metastasis via transcriptional and epigenetic control of E-cadherin expression. Cancer Research. 74: 7357-70. PMID 25348955 DOI: 10.1158/0008-5472.CAN-14-0666  1
2014 Krueger AB, Drasin DJ, Lea WA, Patrick AN, Patnaik S, Backos DS, Matheson CJ, Hu X, Barnaeva E, Holliday MJ, Blevins MA, Robin TP, Eisenmesser EZ, Ferrer M, Simeonov A, ... ... Ford HL, et al. Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration. The Journal of Biological Chemistry. 289: 16349-61. PMID 24755226 DOI: 10.1074/jbc.M114.566729  1
2014 O'Brien JH, Hernandez-Lagunas L, Artinger KB, Ford HL. MicroRNA-30a regulates zebrafish myogenesis through targeting the transcription factor Six1. Journal of Cell Science. 127: 2291-301. PMID 24634509 DOI: 10.1242/jcs.143677  1
2014 Kohrt D, Crary J, Zimmer M, Patrick AN, Ford HL, Hinds PW, Grossel MJ. CDK6 binds and promotes the degradation of the EYA2 protein. Cell Cycle (Georgetown, Tex.). 13: 62-71. PMID 24196439 DOI: 10.4161/cc.26755  1
2013 Patrick AN, Cabrera JH, Smith AL, Chen XS, Ford HL, Zhao R. Structure-function analyses of the human SIX1-EYA2 complex reveal insights into metastasis and BOR syndrome. Nature Structural & Molecular Biology. 20: 447-53. PMID 23435380 DOI: 10.1038/nsmb.2505  1
2013 Krueger AB, Dehdashti SJ, Southall N, Marugan JJ, Ferrer M, Li X, Ford HL, Zheng W, Zhao R. Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity. Journal of Biomolecular Screening. 18: 85-96. PMID 22820394 DOI: 10.1177/1087057112453936  0.52
2013 Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene. 32: 1341-50. PMID 22580613 DOI: 10.1038/onc.2012.164  1
2012 Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Research : Bcr. 14: R100. PMID 22765220 DOI: 10.1186/bcr3219  1
2012 Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P, Ford HL. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Molecular Cancer Research : McR. 10: 1098-108. PMID 22723308 DOI: 10.1158/1541-7786.MCR-12-0086  1
2012 Smith AL, Robin TP, Ford HL. Molecular pathways: targeting the TGF-β pathway for cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4514-21. PMID 22711703 DOI: 10.1158/1078-0432.CCR-11-3224  1
2012 Wang CA, Jedlicka P, Patrick AN, Micalizzi DS, Lemmer KC, Deitsch E, Casás-Selves M, Harrell JC, Ford HL. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. The Journal of Clinical Investigation. 122: 1895-906. PMID 22466647 DOI: 10.1172/JCI59858  1
2012 Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht K. Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer. Gynecologic Oncology. 125: 451-7. PMID 22333994 DOI: 10.1016/j.ygyno.2012.02.007  1
2012 Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan AC, Ford HL. The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene. 31: 5162-71. PMID 22286770 DOI: 10.1038/onc.2012.11  1
2012 Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, Ford HL. Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene. 31: 552-62. PMID 21706047 DOI: 10.1038/onc.2011.259  1
2011 Drasin DJ, Robin TP, Ford HL. Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Research : Bcr. 13: 226. PMID 22078097 DOI: 10.1186/bcr3037  1
2011 Menke C, Bin L, Thorburn J, Behbakht K, Ford HL, Thorburn A. Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents. Cancer Research. 71: 1883-92. PMID 21363923 DOI: 10.1158/0008-5472.CAN-10-2252  1
2011 Menke C, Goncharov T, Qamar L, Korch C, Ford HL, Behbakht K, Thorburn A. TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro. Plos One. 6: e14527. PMID 21264287 DOI: 10.1371/journal.pone.0014527  1
2010 Micalizzi DS, Wang CA, Farabaugh SM, Schiemann WP, Ford HL. Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. Cancer Research. 70: 10371-80. PMID 21056993 DOI: 10.1158/0008-5472.CAN-10-1354  1
2010 Ford HL, Thompson EW. Mammary gland studies as important contributors to the cause of epithelial mesenchymal plasticity in malignancy. Journal of Mammary Gland Biology and Neoplasia. 15: 113-5. PMID 20544376 DOI: 10.1007/s10911-010-9182-0  1
2010 Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. Journal of Mammary Gland Biology and Neoplasia. 15: 117-34. PMID 20490631 DOI: 10.1007/s10911-010-9178-9  1
2010 Coletta RD, McCoy EL, Burns V, Kawakami K, McManaman JL, Wysolmerski JJ, Ford HL. Characterization of the Six1 homeobox gene in normal mammary gland morphogenesis. Bmc Developmental Biology. 10: 4. PMID 20074369 DOI: 10.1186/1471-213X-10-4  1
2009 Micalizzi DS, Ford HL. Epithelial-mesenchymal transition in development and cancer. Future Oncology (London, England). 5: 1129-43. PMID 19852726 DOI: 10.2217/fon.09.94  1
2009 Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Barón AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, Schiemann WP, Ford HL. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. The Journal of Clinical Investigation. 119: 2678-90. PMID 19726885 DOI: 10.1172/JCI37815  1
2009 McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. The Journal of Clinical Investigation. 119: 2663-77. PMID 19726883 DOI: 10.1172/JCI37691  1
2009 Patrick AN, Schiemann BJ, Yang K, Zhao R, Ford HL. Biochemical and functional characterization of six SIX1 Branchio-oto-renal syndrome mutations. The Journal of Biological Chemistry. 284: 20781-90. PMID 19497856 DOI: 10.1074/jbc.M109.016832  1
2009 McCoy EL, Kawakami K, Ford HL, Coletta RD. Expression of Six1 homeobox gene during development of the mouse submandibular salivary gland. Oral Diseases. 15: 407-13. PMID 19371398 DOI: 10.1111/j.1601-0825.2009.01560.x  1
2008 Christensen KL, Patrick AN, McCoy EL, Ford HL. The six family of homeobox genes in development and cancer. Advances in Cancer Research. 101: 93-126. PMID 19055944 DOI: 10.1016/S0065-230X(08)00405-3  1
2008 Coletta RD, Christensen KL, Micalizzi DS, Jedlicka P, Varella-Garcia M, Ford HL. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. Cancer Research. 68: 2204-13. PMID 18381426 DOI: 10.1158/0008-5472.CAN-07-3141  1
2007 Behbakht K, Qamar L, Aldridge CS, Coletta RD, Davidson SA, Thorburn A, Ford HL. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Research. 67: 3036-42. PMID 17409410 DOI: 10.1158/0008-5472.CAN-06-3755  1
2007 Christensen KL, Brennan JDG, Aldridge CS, Ford HL. Cell cycle regulation of the human Six1 homeoprotein is mediated by APCCdh1 Oncogene. 26: 3406-3414. PMID 17130831 DOI: 10.1038/sj.onc.1210122  0.6
2005 Miller MM, Wang C, Parisini E, Coletta RD, Goto RM, Lee SY, Barral DC, Townes M, Roura-Mir C, Ford HL, Brenner MB, Dascher CC. Characterization of two avian MHC-like genes reveals an ancient origin of the CD1 family. Proceedings of the National Academy of Sciences of the United States of America. 102: 8674-9. PMID 15939884 DOI: 10.1073/pnas.0500105102  1
2005 Reichenberger KJ, Coletta RD, Schulte AP, Varella-Garcia M, Ford HL. Gene amplification is a mechanism of Six1 overexpression in breast cancer. Cancer Research. 65: 2668-75. PMID 15805264 DOI: 10.1158/0008-5472.CAN-04-4286  1
2004 Coletta RD, Christensen K, Reichenberger KJ, Lamb J, Micomonaco D, Huang L, Wolf DM, Müller-Tidow C, Golub TR, Kawakami K, Ford HL. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proceedings of the National Academy of Sciences of the United States of America. 101: 6478-83. PMID 15123840 DOI: 10.1073/pnas.0401139101  0.48
2004 Coletta RD, Jedlicka P, Gutierrez-Hartmann A, Ford HL. Transcriptional control of the cell cycle in mammary gland development and tumorigenesis. Journal of Mammary Gland Biology and Neoplasia. 9: 39-53. PMID 15082917 DOI: 10.1023/B:JOMG.0000023587.40966.f6  1
2003 Wang C, Perera TV, Ford HL, Dascher CC. Characterization of a divergent non-classical MHC class I gene in sharks. Immunogenetics. 55: 57-61. PMID 12715247 DOI: 10.1007/s00251-003-0542-4  1
2000 Ford HL, Landesman-Bollag E, Dacwag CS, Stukenberg PT, Pardee AB, Seldin DC. Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein. The Journal of Biological Chemistry. 275: 22245-54. PMID 10801845 DOI: 10.1074/jbc.M002446200  1
2000 Guan RJ, Ford HL, Fu Y, Li Y, Shaw LM, Pardee AB. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Research. 60: 749-55. PMID 10676663  1
1999 Ford HL, Pardee AB. Cancer and the cell cycle. Journal of Cellular Biochemistry. 166-72. PMID 10629116 DOI: 10.1002/(SICI)1097-4644(1999)75:32+<166::AID-JCB20>3.0.CO;2-J  1
1998 Ford HL. Homeobox genes: A link between development, cell cycle, and cancer? Cell Biology International. 22: 397-400. PMID 10328847 DOI: 10.1006/cbir.1998.0329  1
1998 Ford HL, Pardee AB. The S phase: beginning, middle, and end: a perspective. Journal of Cellular Biochemistry. Supplement. 30: 1-7. PMID 9893249  1
1998 Ford HL, Kabingu EN, Bump EA, Mutter GL, Pardee AB. Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America. 95: 12608-13. PMID 9770533 DOI: 10.1073/pnas.95.21.12608  1
1997 Ford HL, Silver DL, Kachar B, Sellers JR, Zain SB. Effect of Mts1 on the structure and activity of nonmuscle myosin II. Biochemistry. 36: 16321-7. PMID 9405067 DOI: 10.1021/bi971182l  1
1995 Ford HL, Zain SB. Interaction of metastasis associated Mts1 protein with nonmuscle myosin. Oncogene. 10: 1597-605. PMID 7731714  1
1995 Ford HL, Salim MM, Chakravarty R, Aluiddin V, Zain SB. Expression of Mts1, a metastasis-associated gene, increases motility but not invasion of a nonmetastatic mouse mammary adenocarcinoma cell line. Oncogene. 11: 2067-75. PMID 7478526  1
1993 Tulchinsky E, Kramerov D, Ford HL, Reshetnyak E, Lukanidin E, Zain S. Characterization of a positive regulatory element in the mts1 gene Oncogene. 8: 79-86. PMID 8423998  1
1992 Tulchinsky E, Ford HL, Kramerov D, Reshetnyak E, Grigorian M, Zain S, Lukanidin E. Transcriptional analysis of the mts1 gene with specific reference to 5' flanking sequences. Proceedings of the National Academy of Sciences of the United States of America. 89: 9146-50. PMID 1329089  1
Low-probability matches
2017 Thorburn J, Staskiewicz L, Goodall ML, Dimberg L, Frankel AE, Ford HL, Thorburn A. Non-cell-autonomous Effects of Autophagy Inhibition in Tumor Cells Promote Growth of Drug-resistant Cells. Molecular Pharmacology. 91: 58-64. PMID 27974637 DOI: 10.1124/mol.116.106070  0.24
2013 Cieply B, Farris J, Denvir J, Ford HL, Frisch SM. Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2. Cancer Research. 73: 6299-309. PMID 23943797 DOI: 10.1158/0008-5472.CAN-12-4082  0.2
2013 Auvergne RM, Sim FJ, Wang S, Chandler-Militello D, Burch J, Al Fanek Y, Davis D, Benraiss A, Walter K, Achanta P, Johnson M, Quinones-Hinojosa A, Natesan S, Ford HL, Goldman SA. Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. Cell Reports. 3: 2127-41. PMID 23727239 DOI: 10.1016/j.celrep.2013.04.035  0.2
2003 Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, Zahnow CA, Patterson N, Golub TR, Ewen ME. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 114: 323-34. PMID 12914697 DOI: 10.1016/S0092-8674(03)00570-1  0.2
2001 Geng Y, Yu Q, Whoriskey W, Dick F, Tsai KY, Ford HL, Biswas DK, Pardee AB, Amati B, Jacks T, Richardson A, Dyson N, Sicinski P. Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proceedings of the National Academy of Sciences of the United States of America. 98: 13138-43. PMID 11687642 DOI: 10.1073/pnas.231487798  0.16
1998 Ford HL, Pardee AB. The S phase: Beginning, middle, and end: A perspective. Journal of Cellular Biochemistry. 72: 1-7. PMID 29345824 DOI: 10.1002/(SICI)1097-4644(1998)72:30/31+<1::AID-JCB2>3.0.CO;2-E  0.16
2014 Powell DR, O'Brien JH, Ford HL, Artinger KB. Neural Crest Cells and Cancer. Insights into Tumor Progression. Neural Crest Cells: Evolution, Development and Disease. 335-357. DOI: 10.1016/B978-0-12-401730-6.00017-X  0.08
2015 Ford HL, Ravelo AC, Polissar PJ. Reduced El Niño-Southern Oscillation during the Last Glacial Maximum. Science (New York, N.Y.). 347: 255-8. PMID 25593181 DOI: 10.1126/science.1258437  0.04
2015 Ford HL, Ravelo AC, Dekens PS, Lariviere JP, Wara MW. The evolution of the equatorial thermocline and the early Pliocene El Padre mean state Geophysical Research Letters. DOI: 10.1002/2015GL064215  0.04
2015 Lynch-Stieglitz J, Polissar PJ, Jacobel AW, Hovan SA, Pockalny RA, Lyle M, Murray RW, Ravelo AC, Bova SC, Dunlea AG, Ford HL, Hertzberg JE, Wertman CA, Maloney AE, Shackford JK, et al. Glacial-interglacial changes in central tropical Pacific surface seawater property gradients Paleoceanography. DOI: 10.1002/2014PA002746  0.04
2014 Ravelo AC, Lawrence KT, Fedorov A, Ford HL. Comment on "A 12-million-year temperature history of the tropical Pacific Ocean". Science (New York, N.Y.). 346: 1467. PMID 25525238 DOI: 10.1126/science.1257618  0.04
2012 LaRiviere JP, Ravelo AC, Crimmins A, Dekens PS, Ford HL, Lyle M, Wara MW. Late Miocene decoupling of oceanic warmth and atmospheric carbon dioxide forcing. Nature. 486: 97-100. PMID 22678287 DOI: 10.1038/nature11200  0.04
2012 McFadden E, Horton MC, Ford HL, Gilworth G, McFadden M, Tennant A. Screening for the risk of job loss in multiple sclerosis (MS): development of an MS-specific Work Instability Scale (MS-WIS). Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 862-70. PMID 22041093 DOI: 10.1177/1352458511428463  0.04
2012 Ford HL, Ravelo AC, Hovan S. A deep Eastern Equatorial Pacific thermocline during the early Pliocene warm period Earth and Planetary Science Letters. 355: 152-161. DOI: 10.1016/j.epsl.2012.08.027  0.04
2010 Ford HL, Schellenberg SA, Becker BJ, Deutschman DL, Dyck KA, Koch PL. Evaluating the skeletal chemistry of Mytilus californianus as a temperature proxy: Effects of microenvironment and ontogeny Paleoceanography. 25. DOI: 10.1029/2008PA001677  0.04
2008 Alty JE, Ford HL. Multi-system complications of hypothermia: A case of recurrent episodic hypothermia with a review of the pathophysiology of hypothermia Postgraduate Medical Journal. 84: 282-286. PMID 18644917 DOI: 10.1136/pgmj.2007.066050  0.04
2006 Ford HL. The effect of consent guidelines on a multiple sclerosis register Multiple Sclerosis. 12: 104-107. PMID 16459727 DOI: 10.1191/135248506ms1257sr  0.04
2002 Lorenzi AR, Ford HL. Multiple sclerosis and pregnancy Postgraduate Medical Journal. 78: 460-464. PMID 12185217 DOI: 10.1136/pmj.78.922.460  0.04
2002 Ford HL, Gerry E, Johnson M, Williams R. A prospective study of the incidence, prevalence and mortality of multiple sclerosis in Leeds Journal of Neurology. 249: 260-265. PMID 11993523 DOI: 10.1007/s004150200002  0.04
2002 Ford HL, Johnson M, Fear J. A multi-district model for the management of disease-modifying treatments in multiple sclerosis British Journal of Clinical Governance. 7: 267-272. DOI: 10.1108/14664100210446650  0.04
2001 Ford HL, Gerry E, Johnson MH, Tennant A. Health status and quality of life of people with multiple sclerosis Disability and Rehabilitation. 23: 516-521. PMID 11432648 DOI: 10.1080/09638280010022090  0.04
2001 Ford HL, Gerry E, Tennant A, Whalley D, Haigh R, Johnson MH. Developing a disease-specific quality of life measure for people with multiple sclerosis Clinical Rehabilitation. 15: 247-258. PMID 11386394 DOI: 10.1191/026921501673658108  0.04
1998 Ford HL, Gerry E, Airey CM, Vail A, Johnson MH, Williams DRR. The prevalence of multiple sclerosis in the Leeds Health Authority Journal of Neurology Neurosurgery and Psychiatry. 64: 605-610. PMID 9598675  0.04
1996 Ford HL, Johnson MH, Rigby AS. Variation between observers in classifying multiple sclerosis Journal of Neurology, Neurosurgery, and Psychiatry. 61: 418. PMID 8890785  0.04
1995 Wright JP, Ford HL. Bacterial meningitis in developing countries. Tropical Doctor. 25: 5-8. PMID 7886841 DOI: 10.1177/004947559502500102  0.04
1995 Ford HL, Johnson MH. Telling your patient he/she has multiple sclerosis Postgraduate Medical Journal. 71: 449-452. PMID 7567749 DOI: 10.1136/pgmj.71.838.449  0.04
2017 Tavares ALP, Cox TC, Maxson RM, Ford HL, Clouthier DE. Negative regulation of Endothelin signaling by SIX1 is required for proper maxillary development. Development (Cambridge, England). PMID 28455376 DOI: 10.1242/dev.145144  0.01
2016 Vinjam MR, Shanmugarajah P, Ford HL. Ophthalmoplegia heralding the onset of anti-amphiphysin related paraneoplastic stiff person syndrome Journal of Neurology. 1-2. DOI: 10.1007/s00415-016-8078-3  0.01
2015 Andrianabela S, Hariharan R, Ford HL, Chamberlain MA. A rehabilitation training partnership in Madagascar Journal of Rehabilitation Medicine. 47: 682-687. DOI: 10.2340/16501977-1997  0.01
2014 Cosgrove J, Alli S, Ramadan H, Ford HL. Myocarditis and diffuse skeletal muscle oedema: new features of neuromyelitis optica spectrum disorder? A case report. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 120-2. PMID 23846353 DOI: 10.1177/1352458513495939  0.01
2014 Blount TH, Cigrang JA, Foa EB, Ford HL, Peterson AL. Intensive Outpatient Prolonged Exposure for Combat-Related PTSD: A Case Study Cognitive and Behavioral Practice. 21: 89-96. DOI: 10.1016/j.cbpra.2013.05.004  0.01
2007 Thind BB, Ford HL. Maintaining Psoroptes ovis (Acari: Psoroptidae) off-host in the laboratory Experimental and Applied Acarology. 43: 205-211. PMID 17968662 DOI: 10.1007/s10493-007-9116-8  0.01
2007 Thind BB, Ford HL. Assessment of susceptibility of the poultry red mite Dermanyssus gallinae (Acari: Dermanyssidae) to some acaricides using an adapted filter paper based bioassay Veterinary Parasitology. 144: 344-348. PMID 17157988 DOI: 10.1016/j.vetpar.2006.10.002  0.01
2006 Carroll KM, Easton CJ, Nich C, Hunkele KA, Neavins TM, Sinha R, Ford HL, Vitolo SA, Doebrick CA, Rounsaville BJ. The use of contingency management and motivational/skills-building therapy to treat young adults with marijuana dependence. Journal of Consulting and Clinical Psychology. 74: 955-66. PMID 17032099 DOI: 10.1037/0022-006X.74.5.955  0.01
2006 Thind BB, Ford HL. Laboratory studies on the use of two new arenas to evaluate the impact of the predatory mites Blattisocius tarsalis and Cheyletus eruditus on residual populations of the stored product mite Acarus siro Experimental and Applied Acarology. 38: 167-180. PMID 16596350 DOI: 10.1007/s10493-005-5829-8  0.01
2003 Thind BB, Ford HL. A simple pump-assisted method for collecting live, undamaged Psoroptes ovis from sheep using circulating saline Veterinary Parasitology. 114: 215-222. PMID 12788256 DOI: 10.1016/S0304-4017(03)00138-9  0.01
1986 Ford HL. FLOCCULANT TESTING Chem Reagents in the Min Process Ind. 255-260.  0.01
1960 Ford HL. Planning problems of temporary townships overseas Planning Outlook Series 1. 5: 31-39. DOI: 10.1080/09640566008730615  0.01
Hide low-probability matches.